Denali Therapeutics
As of the edition of 20 October 2026, Denali Therapeutics runs 12 drugs, 1 of them marketed; it is on route A at 2 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 7 |
| Went quiet | 2 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 12 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Tividenofusp alfa | Ends 2038 (computed from the first US licence) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 2 targets, route B at 0 targets.
| Target | Route |
|---|---|
| None Leucine-rich repeat serine/threonine-protein kinase 2 | Route A |
| RIPK1 Receptor-interacting serine/threonine-protein kinase 1 | Route A |
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Denali Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 11 trials led
- Nutrition and metabolism: 7 trials led
- Inherited and neonatal: 5 trials led